Loading…
Larimar Therapeutics, Inc. is projected to decline to $4.16 by 2027, a -3% move from its current price of $4.28. LRMR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $4.08 | $4.28 | $4.49 | -0.02% |
| Jul 13 | $4.00 | $4.28 | $4.57 | -0.04% |
| Jul 14 | $3.94 | $4.28 | $4.64 | -0.05% |
| Jul 15 | $3.89 | $4.28 | $4.70 | -0.07% |
| Jul 16 | $3.85 | $4.28 | $4.75 | -0.09% |
| Jul 17 | $3.81 | $4.28 | $4.80 | -0.11% |
| Jul 18 | $3.77 | $4.27 | $4.84 | -0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.77 | $4.27 | $4.84 | -0.13% |
| Week 2 | $3.58 | $4.27 | $5.09 | -0.25% |
| Week 3 | $3.44 | $4.26 | $5.29 | -0.38% |
| Week 4 | $3.32 | $4.26 | $5.46 | -0.51% |
| Week 5 | $3.22 | $4.25 | $5.62 | -0.63% |
| Week 6 | $3.13 | $4.25 | $5.76 | -0.76% |
| Week 7 | $3.05 | $4.24 | $5.90 | -0.88% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
The company is based in Bala Cynwyd, Pennsylvania.
LRMR operates in the Healthcare sector and is currently priced at $4.13. The stock has a market capitalization of $429.04M and is ranked 3194 by market size. The current price provides a reference point for the near term, with a multi-year forecast outlining potential upside across several future milestones.
A major floor 38.3% below — a decisive break under it would weaken the trend.
The nearest floor, 28.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 32.9% above — clearing it would confirm fresh momentum.
Key LRMR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LRMR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.74 | Buy | $3.86 | Buy |
| MA 10 | $3.51 | Buy | $3.67 | Buy |
| MA 20 | $3.54 | Buy | $3.58 | Buy |
| MA 50 | $3.62 | Buy | $3.69 | Buy |
| MA 100 | $4.14 | Buy | $3.84 | Buy |
| MA 200 | $3.95 | Buy | $3.90 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.81 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 237.59 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.10 | Buy |
| ROC (12) | 16.30 | Buy |
| Bollinger %B (20,2) | 1.15 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.18 | Sell |
| Awesome (5,34) | 0.26 | Buy |
| Ultimate (7,14,28) | 84.07 | Sell |
| Momentum (10) | 0.78 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 4.09 | Buy |
| ADX (14) | 16.02 | Neutral |
| ATR (14) | 0.16 | Info |
The near-term technical picture is bullish, with RSI(14) at 60. The stock trades above both the SMA50 of $3.62 and the SMA200 of $3.95, which can be interpreted as a constructive trend signal.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.81 | $4.28 | $5.82 | 0% | Neutral | |
| $3.09 | $4.16 | $6.04 | -3% | Neutral | |
| $2.85 | $4.04 | $6.21 | -6% | Neutral | |
| $3.00 | $4.45 | $7.14 | +4% | Neutral | |
| $3.65 | $5.64 | $9.39 | +32% | Bullish | |
| $4.34 | $6.94 | $11.94 | +62% | Bullish | |
| $3.96 | $6.57 | $11.62 | +53% | Bullish | |
| $3.80 | $6.52 | $11.83 | +52% | Bullish | |
| $4.05 | $7.18 | $13.33 | +68% | Bullish | |
| $3.40 | $6.22 | $11.80 | +45% | Bullish | |
| $4.85 | $10.29 | $21.32 | +140% | Bullish | |
| $8.87 | $19.70 | $45.32 | +360% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.81 | $4.28 | $5.24 | +0.00% |
| August 2026 | $3.45 | $4.16 | $5.20 | -2.90% |
| September 2026 | $3.45 | $4.21 | $5.36 | +1.30% |
| October 2026 | $3.65 | $4.50 | $5.82 | +6.83% |
| November 2026 | $3.64 | $4.53 | $5.93 | +0.68% |
| December 2026 | $3.50 | $4.39 | $5.82 | -2.98% |
Click any year to see its month-by-month LRMR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, LRMR could reach as high as $5.82, with a base case around $4.28 and support toward $2.81 — roughly 0% from $4.28. Price action looks broadly range-bound.
Expect LRMR to range from $3.09 to $6.04 through 2027. The $4.16 average target implies a -3% move from current prices. That is -3% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The LRMR price prediction for 2028 points to an average of $4.04 (low $2.85, high $6.21) — a potential decline of -6% on today's $4.28. Price action looks broadly range-bound.
In 2029, LRMR is projected to trade between $3.00 and $7.14, averaging $4.45 — a potential gain of +4% from today's $4.28. That is up +10% on the projected 2028 average. A consolidation phase looks the most probable path here.
Larimar Therapeutics, Inc.'s 2030 outlook centres on $5.64, within a $3.65 to $9.39 range. That is up +27% on the projected 2029 average. That marks a +32% change versus current levels. Momentum favours further upside here.
By 2031, LRMR could reach as high as $11.94, with a base case around $6.94 and support toward $4.34 — roughly +62% from $4.28. Buyers look set to stay in control over this stretch.
Expect LRMR to range from $3.96 to $11.62 through 2032. The $6.57 average target implies a +53% move from current prices. That is -5% versus the projected 2031 average. Momentum favours further upside here.
The LRMR price prediction for 2033 points to an average of $6.52 (low $3.80, high $11.83) — a potential gain of +52% on today's $4.28. Buyers look set to stay in control over this stretch.
In 2034, LRMR is projected to trade between $4.05 and $13.33, averaging $7.18 — a potential gain of +68% from today's $4.28. That is up +10% on the projected 2033 average. Momentum favours further upside here.
Larimar Therapeutics, Inc.'s 2035 outlook centres on $6.22, within a $3.40 to $11.80 range. That is -13% versus the projected 2034 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, LRMR could reach as high as $21.32, with a base case around $10.29 and support toward $4.85 — roughly +140% from $4.28. Momentum favours further upside here.
Expect LRMR to range from $8.87 to $45.32 through 2050. The $19.70 average target implies a +360% move from current prices. That is up +91% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in LRMR today (≈ 233.64486 LRMR) could be worth
$4,603.76
+$3,603.76 (+360%) by 2050 · US Dollar
Based on the average projected LRMR price of $19.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LRMRwould be worth at today's price.
$1,000 invested in LRMR on Jul 10, 2025 (≈ 287.35632 LRMR) would be worth
$1,229.89
+$229.89 (+23.0%) today · 1.23× · US Dollar
Based on a LRMR entry price of $3.48 vs. today's $4.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.26 | $1,312.88 | +31.3% |
| 1 month ago | $3.44 | $1,244.19 | +24.4% |
| 3 months ago | $4.85 | $882.47 | -11.8% |
| 6 months ago | $3.25 | $1,316.92 | +31.7% |
| 1 year ago | $3.48 | $1,229.89 | +23.0% |
| All time (5.0y) ago | $11.48 | $372.82 | -62.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LRMR forecast.
Our base-case forecast reaches $8.60 around 2040.
Implied market cap at $8.60: $893.39M
The multi-year forecast shows a path of rising averages and substantial upside. In 2030, the average price is forecast at $5.33 with a min of $3.43 and a max of $8.93, representing a 29 ROI with bullish sentiment. By 2040, the average is projected at $9.60 (ROI 132.4) and by 2050 at $18.19 (ROI 340.5), with bullish sentiment persisting.
These figures imply meaningful long-run upside but remain contingent on conditions that can affect clinical-stage biotechnology outcomes.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $5.33, a minimum of $3.43, and a maximum of $8.93, with an ROI of 29 and a bullish sentiment.
The forecast indicates long-run upside with an average price of $5.33 in 2030 and potential to $18.19 by 2050, with ROIs of 29 in 2030, 132.4 in 2040, and 340.5 in 2050, all under a bullish outlook but not guaranteed.
Yes. The 2050 forecast shows an average of $18.19 and a max of $41.84, indicating the potential to exceed $20 given the up to $41.84 max in 2050.
The current price is $4.13.
The 30-day range is from $3.01 to $5.66.
Larimar Therapeutics, Inc. Community Discussion
0Share your Larimar Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.